As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement
Sanofi is in the middle of a heated controversy in the Philippines that shows no signs of dying out anytime soon.
Over the last few …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
